High-dose immediate-release tablet manufacture with ASIMPLEX 250 mg lyophilized powder for solution for infusion as the reference active pharmaceutical ingredient places aciclovir at drug loadings that force simultaneous control of blend uniformity, tensile strength, and dissolution lag. When the active is converted to a dry oral form, the lyophilization step in the supplied reference material is not directly replicated in the tablet process; instead, particle-size distribution, moisture sorption, and bulk density of the API are measured before choosing between direct compression and wet granulation. For a 200 mg aciclovir tablet core with total mass 320–450 mg, the active occupies 44.4–62.5 wt%; a 400 mg core at 550–750 mg total mass reaches 53.3–72.7 wt%; and an 800 mg core at 1,050–1,350 mg total mass reaches 59.3–76.2 wt%. The upper boundaries of these ranges require granulation because direct compression blends at those loadings show unacceptable segregation and capping risk on rotary tablet presses.

Release testing for these tablet strengths is anchored to USP <711> dissolution, USP <905> uniformity of dosage units, USP <701> disintegration, and the corresponding Ph. Eur. 2.9.3 and Ph. Eur. 2.9.5 methods where the submission follows European pharmacopoeial criteria. In-process control under 21 CFR 211.110 requires blend uniformity sampling at defined intervals after the final lubrication step; an acceptance limit of 90.0–110.0% label claim per sample with RSD ≤5.0% is commonly applied during process validation. Residual solvent control follows USP <467> and ICH Q3C when granulation solvents other than water are introduced.

Wet granulation is executed in a high-shear granulator with a binder solution of povidone K30 at 2–4% w/w in water; the wet mass is dried in a fluid-bed dryer to a final LOD of 1.5–3.0% before conical milling through a 0.8–1.2 mm screen. Dry granulate is then blended with croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate in a diffusion mixer; lubricant is added as the final component at 0.5–1.0% w/w and mixed for 3–5 min to avoid overlubrication that delays disintegration. Compression is performed on a rotary tablet press with main compression force 10–30 kN; tablet hardness is held at 8–15 kp to balance friability below 0.5% against disintegration below 15 min in water at 37±1 °C. Process drift that increases granule moisture above 3.5% leads to picking on upper punches; moisture below 1.0% increases capping at the high-dose edges.

Terminal dosage forms include immediate-release tablets at 200 mg, 400 mg, and 800 mg strengths packed in blisters or HDPE containers. The 800 mg tablet is the most compression-stressed form and requires the narrowest granule density specification because press speed above 40 rpm can amplify weight variation when the granule fraction above 850 μm exceeds 15%.

What Lyophilization Cycle Parameters Govern Sterile Infusion Vials?

Lyophilization of aciclovir sodium for infusion is governed by the interaction of cake collapse temperature, chamber pressure, and residual moisture after secondary drying. ASIMPLEX 250 mg lyophilized powder for solution for infusion is prepared by aseptically filling a filtered solution containing aciclovir sodium equivalent to 250 mg aciclovir per vial, adjusted to pH 11.0–11.8 with 1 mol/L sodium hydroxide, into depyrogenated Type I glass vials. The fill volume before freezing is typically 5–10 mL; after lyophilization and reconstitution with 10 mL Water for Injection, the resulting concentration is 25 mg/mL. Further dilution for infusion is performed with 0.9% w/v sodium chloride injection or 5% w/v dextrose injection to a final concentration between 1 mg/mL and 7 mg/mL.

Cycle development uses freeze-drying microscopy to measure collapse temperature; the shelf temperature in primary drying is maintained at least 2–5 °C below that value. Representative operating ranges observed in production-scale units include freezing at -40 to -45 °C for 2–3 h, primary drying at 100–200 mTorr chamber pressure with shelf temperature -20 to -25 °C for 24–48 h, and secondary drying at 25–35 °C with pressure 50–100 mTorr until residual moisture is ≤1.0% w/w. Cake collapse in outer vial rows is a documented scale-up failure mode when shelf temperature homogeneity exceeds ±1.5 °C and the cycle is designed only from center-point thermocouple data. Vial sealing under partial vacuum or nitrogen after drying requires residual oxygen headspace below 2.0% to limit oxidative degradation during shelf life.

Release and stability testing is anchored to the USP Acyclovir for Injection monograph and the following parametric tests: USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter in injections, USP <790> visible particulates, and USP <1207> container closure integrity. The European pharmacopoeial counterpart methods include Ph. Eur. 2.6.1, Ph. Eur. 2.6.14, and Ph. Eur. 2.9.19. Regulatory process-control expectations are set by 21 CFR 211.113, 21 CFR 211.167, and EU GMP Annex 1 for aseptic processing and lyophilization.

Finished presentations are 250 mg and 500 mg single-dose vials with elastomeric closures and flip-off seals; no antimicrobial preservative is included because the product is a single-dose sterile product. Terminal sterilization is not used because of thermal degradation in solution; aseptic processing followed by lyophilization is the only route that preserves the 25 mg/mL reconstitution label claim without exceeding specified degradation product thresholds. If a bulking agent is introduced, collapse temperature shifts upward and must be re-established by freeze-drying microscopy because published data for this specific configuration is limited.

Roller Compaction and Encapsulation of Aciclovir Granules in Hard Capsule Shells

Capsule filling with aciclovir requires granulation when the API content exceeds 50 wt% because untreated milled aciclovir exhibits flow characteristics that cause fill weight drift in tamping-pin and dosator machines. A 200 mg hard gelatin capsule with total fill mass 300–420 mg places the active at 47.6–66.7 wt%; roller-compacted granules with apparent density 0.55–0.75 g/mL provide sufficient flow and reduce segregation during encapsulation.

Release testing follows the USP Acyclovir Capsules monograph, USP <711> dissolution, USP <905> content uniformity, USP <701> disintegration, and Ph. Eur. 2.9.3 and Ph. Eur. 2.9.5 for European filings. In-process testing under 21 CFR 211.110 includes capsule fill weight at 15–20 min intervals and metal detection after capsule sorting. Dissolution acceptance at 45 min in 900 mL of 0.1 N hydrochloric acid at 37±0.5 °C with paddle speed 50 rpm is typically set in early development; the final specification is product-specific and must be justified with in vivo correlation data.

Dry blending is carried out in a twin-shell blender with API, diluent, disintegrant, and binder; magnesium stearate is added after blending at 0.5–1.0% w/w. The blend is compacted on a roller compactor using ribbed rolls at specific pressure 3–6 kN/cm and roll speed 5–10 rpm; the resulting ribbon is milled through an oscillating mill with a 1.0 mm screen. Granules outside the 150–850 μm fraction are either recycled at ≤20% of the fresh feed or rejected because excessive fines raise fill weight variation. Encapsulation is performed on an automatic capsule machine with dosator or tamping-pin configuration at 50–90 cycles/min; fill weight is maintained at ±5% of target. Published data for roller-compacted aciclovir capsule formulations is limited; ribbon density and granule porosity should be confirmed with development trials before commercial batch commitment.

Finished capsule dosage forms are typically 200 mg aciclovir in size 1 or size 2 hard gelatin or hypromellose shells, packed in HDPE bottles with desiccant if moisture uptake above 3.0% is detected during stability. The capsule route is used where patients require a solid oral form without tablet swallowing difficulties; it is not a modified-release platform for this active substance.

In oral suspension manufacturing, particle-size control of the active substance is determined before any wetting agent is introduced because aciclovir powder with a high fine fraction forms a slowly dispersing sediment that complicates reconstitution and dose uniformity. A dry granule or powder blend intended for reconstitution to 200 mg/5 mL aciclovir oral suspension is formulated on a batch basis so that the final suspension contains 200 mg aciclovir in each 5 mL dose after addition of 60–70 mL water and shaking.

Release testing is controlled by the USP Acyclovir for Oral Suspension monograph where applicable. For reconstitutable granules, dose uniformity after reconstitution is verified by a validated HPLC method meeting the intent of USP <905>, and deliverable volume is checked with USP <698>. Preservative content is monitored by a stability-indicating HPLC method; sodium benzoate is typically used at 0.1–0.2% of the reconstituted suspension. In-process control under 21 CFR 211.110 includes sachet fill weight and bottle fill volume at defined intervals.

Manufacture begins with screening of aciclovir through a 0.5 mm sieve, followed by dry blending with sucrose, xanthan gum, sodium citrate buffer, and sodium benzoate in a planetary mixer or V-blender. If granulation is used, water is sprayed into the blend and the mass is dried in a fluid-bed dryer at inlet air temperature 50–60 °C to LOD 1.0–2.0%. The dried granulate is milled through a 0.8–1.0 mm screen, filled into 125 mL or 150 mL glass or PET bottles, or sealed into unit-dose sachets for pediatric use. Reconstitution yields a suspension with a representative development target viscosity of 50–150 mPa·s at 25 °C measured by Brookfield viscometer at 50 rpm; this range is targeted to slow sedimentation while maintaining pourability.

Finished forms include 200 mg/5 mL reconstitutable suspension in multi-dose bottles and single-dose sachets containing 200 mg or 400 mg aciclovir as dry granules. In high-humidity packaging lines, moisture ingress above 60% RH during sachet filling requires air conditioning and immediate sealing because the granulated product becomes tacky and loses fill-weight precision.

When Aciclovir Injection Moves from Manufacturer Lyophilization to Ward-Based Reconstitution

Hospital ward reconstitution transfers the manufacturer’s lyophilized vial into an infusion bag under conditions where particulate contamination, pH drift, and incompatibility with polyvinyl chloride administration sets are monitored. A 250 mg vial is reconstituted with 10 mL Water for Injection to yield 25 mg/mL; the dose is then diluted with 0.9% w/v sodium chloride injection or 5% w/v dextrose injection to a final concentration of 1–7 mg/mL. Concentrations above 7 mg/mL are associated with increased risk of phlebitis and should not be used for peripheral infusion.

Compounding of the injectable is performed under USP <797> within an ISO Class 5 PEC located in an ISO Class 7 buffer area; if the work involves a hazardous drug list entry, a closed-system transfer device is used to restrict aerosol generation. Pharmacy process controls include visual inspection after reconstitution, particulate inspection against a light background, and labelling with beyond-use date. The diluted infusion is typically assigned a 12 h beyond-use date at controlled room temperature when prepared under validated aseptic conditions; refrigeration at 2–8 °C may extend stability only when supported by internal stability data.

Reconstitution is performed by slowly injecting WFI into the vial and avoiding vigorous shaking to prevent foam and pH localization; the vial is swirled until the cake dissolves completely. The calculated dose is withdrawn through a 5 μm filter needle or transfer device and injected into the infusion bag. The infusion is administered over 60 min at a controlled rate using an infusion pump; bolus administration is not permitted. In renal-compromised patients, dosing interval and infusion volume are adjusted based on calculated creatinine clearance; the total dose remains within the 1–7 mg/mL concentration boundary.

Ready-to-administer products include 250 mg, 500 mg, 750 mg, and 1,000 mg doses in 100–500 mL infusion containers depending on body weight and renal function. The hospital pathway does not alter the commercial vial closure system; it adds a compounding step that must be captured in batch records when preparation is centralized in the pharmacy.